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Abstract 
Mitochondria implement various cellular functions, including energy production through the electron transport chain 
by oxidative phosphorylation mechanism. These respiratory chains consist of several complexes and protein subunits 
which are encoded by nuclear and mitochondrial genes. Due to mutation susceptibility and repair limitation, more 
aberrations have occurred in mitochondrial DNA in comparison to nuclear DNA. Given the fact that mitochondrial 
DNA lacks introns, mutations almost occur in the coding sequence, which comprises a direct impact on its functions. 
Emerging evidence indicates that mutations in the mitochondrial DNA led to the production of reactive oxygen 
species, disrupted apoptosis, and tumor development. Studies reported various somatic and germline variants in 
mitochondrial DNA related to tumorigenesis. The D-loop region which is the starting point for replication and 
transcription of mitochondrial DNA is the most prevalent site of somatic mutations in solid tumors. The D-loop 
mutations also cause copy number variations which are gaining interest in studies of solid tumors including breast 
cancer, colon cancer, hepatocellular carcinomas, and prostate cancer. Most studies have reported a mitochondrial 
DNA reduction which subsequently prevents apoptosis and promotes metastasis. The mitochondrial DNA region-
specific haplogroups are also involved in the sequence variations due to processes such as genetic drift and adaptive 
selection. 
This review article discusses the biology and function of mitochondria and related genes. By explanation of 
mitochondrial dysfunction caused by different kinds of alterations, we attempt to elucidate the role of mitochondria 
in tumorigenesis. Prominently published articles in this field were reviewed and the role of germline and somatic 
mutations of mitochondrial DNA have been investigated in common cancers. 
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Mitochondria are the main center of energy 
production in the cell that also regulate reactive 
oxygen species (ROS) and apoptosis. In addition to 
these activities, mitochondria are involved in 
signaling, survival, immunity, and cell homeostasis. 
Healthy cells are made up of hundreds of 
mitochondria that supply energy by oxidative 
phosphorylation (OXPHOS) through their electron 
transport chain (ETC) (1, 2). Each mitochondrion 
contains several copies of the mitochondrial genome 
that encode proteins involved in the respiratory 
chain. Mitochondria have their specific and 
independent transcription, translation, and also 
protein assembly machinery (1). Diseases caused by 
mitochondrial dysfunction are either due to 
mutations in the nuclear genome (nDNA) or in the 
mitochondrial genome (mtDNA). Both somatic and 
germline mutations of the mtDNA have been 
detected in a variety of cancers including breast, 
prostate, and colorectal tumors. Cancer cells get 
energy from aerobic glycolysis and the 
accumulation of ROS due to mitochondrial 
dysfunction is their common phenomenon (3, 4). 
Mitochondrial dysfunctions also prevent apoptosis 
and further lead to cancer cell growth (5).  
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The study of mitochondrial function in the 
pathogenesis of cancer is of particular importance. 
In this review, we aimed to delineate the role of 
mitochondria in the development of cancer from 
different perspectives. 
1. Mitochondria 
1.1. Structure and function  
Structurally, mitochondria are double-membrane 
organelles. The inner membrane has a greater 
surface in comparison to the outer membrane, which 
can be diverse based on the tissue and cell types. 
Enzymes involved in the OXPHOS are located in 
the inner membrane (6).  
Adenosine triphosphate (ATP) and nicotinamide 
adenine dinucleotide phosphate (NADPH) are 
produced through the mechanism of OXPHOS in 
the ETC. Besides OXPHOS, mitochondria direct 
several other activities including fatty acid oxidation 
(FAO) and tricarboxylic acid cycle (TCA cycle). A 
variety of amino acids, lipids, carbohydrates, and 
nucleotides are produced by these organelles (7).  
The mitochondrial OXPHOS is controlled by four 
respiratory and one ATP synthase complexes 
including complex I (NADH dehydrogenase), 
complex II (succinate dehydrogenase), complex III 
(ubiquinone-cytochrome c oxidoreductase), 
complex IV (cytochrome C oxidase (COX)) and 
complex V (ATP synthase). All these complexes are 
located in the inner mitochondrial membrane. In 
addition to these complexes, two-electron carriers 
called coenzyme Q (CoQ or ubiquinone) and Cyt c 
is involved in OXPHOS (8).  
Defects in the activity of the complex I due to 
mtDNA mutations play a role in cancer progression 
by increased ROS production. Since only 7 of 46 
polypeptides of complex I are encoded by mtDNA 
and the rest are encoded by nuclear genes, the defect 
in this complex could be due to the nDNA mutation, 
as well (6, 9). In addition to complex I, some 
subunits of the complexes III (1 mtDNA+ 10 
nDNA), IV (3 mtDNA+ 10 nDNA) and V (2 
mtDNA+ 14 nDNA) are encoded by both the 
mtDNA and nDNA, while all 4 subunits of complex 
ІІ are encoded by the nDNA. As a result, alterations 
in the mitochondrial genome disrupt the complexes 
of the mitochondrial respiratory chain except for 
complex ІІ (10).  
Table 1 indicates the nDNA encoded genes related 
to each OXPHOS complex. As presented, they are 
scattered throughout the human genome and vary in 
size and number of amino acids. 
Mitocheckpoint controls mitochondrial function 
and regulates apoptosis and anti-apoptosis signals. 
In the case of mitochondrial dysfunction, 
mitocheckpoint maintains normal mitochondrial 
function but prevents the production of defective 
mitochondria (11). 
The mitocheckpoint proteins interact synergically 
with cell cycle checkpoint proteins. It has been 
shown that in oxidative stress, cyclin B1 
translocated from the nucleus to the cytoplasm and 
mitochondria (12). One of the key mitocheckpoint 
proteins is p53, which plays an important role in 
mtDNA copy number (CN) and mitochondrial 
biogenesis (13). By RNA sequencing Nagano et al 
showed that p53 regulated dihydropyrimidinase-
like 4 (DPYSL4) which is involved in cancer 
invasion and tumor growth. DPYSL4 is linked to 
mitochondrial supercomplexes and is localized in 
mitochondria (14).  
1.2. Human mtDNA 
Exclusively transmitted maternally, the mtDNA 
genome is a circular double-stranded molecule. It 
comprises 16,569 bp and has 37 genes that encode 
12S and 16S ribosomal RNAs (rRNAs), 22 transfer 
RNAs tRNAs), and 13 essential proteins for 
respiration. As shown in Figure 1, 13 essential 
protein-coding genes are; 7 subunits of complex I 
(ND1, ND2, ND3, ND4L, ND4, ND5, and ND6), 1 
complex III subunits (cytochrome b (Cyt b)), 3 
subunits of complex IV (Cyt c oxidase, COXI, 
COXII and COXIII) and 2 subunits of complex V 
(ATP6 and ATP8).  All genes encoding rRNAs and 
proteins involved in the OXPHOS system are 
located on the H-strand except the ND6 gene (15). 
 
Table 1. Nuclear encoded genes related to each OXPHOS complexes. 
Complex Nuclear Genes (Chromosomal location, Amino acid number) 
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I 
NDUFS1(2q33.3, 727aa) ; NDUFS2(1q23.3 , 463aa ) ; NDUFS3(11p11.2 , 264aa) ; NDUFS4(5q11.2 , 
175aa ) ; NDUFS5(1p34.3 , 106aa ); NDUFS6(5p15.33 , 124aa) ; NDUFS7(19p13.3 , 213aa) ; 
NDUFS8(11q13.2 , 210aa) ;  NDUFV1(11q13.2  , 464aa) ;  NDUFV2(18p11.22 , 249aa)  ; 
NDUFV3(21q22.3 , 473aa) ; NDUFA1(Xq24 , 70aa) ; NDUFA2(5q31.3 , 99aa) ; NDUFA3(19q13.42 , 
84aa) ; NDUFA4(7p21.3 , 81aa) ;  NDUFA5(7q31.32, 116aa) ; NDUFA6(22q13.2 , 128aa) ; 
NDUFA7(19p13.2 , 113aa) ; NDUFA8(9q33.2 , 172aa) ; NDUFA9(12p13.32 , 377aa) ; 
NDUFA10(2q37.3 , 355aa) ; NDUFA11(19p13.3 , 141aa) ; NDUFA12(12q22 , 145aa) ; 
NDUFA13(19p13.11 , 144aa) ; NDUFB1(14q32.12 , 58aa) ; NDUFB2(7q34 , 105aa) ; 
NDUFB3(2q33.1 , 98aa) ;     NDUFB4(3q13.33 , 129aa) ; NDUFB5(3q26.33 , 189aa) ; 
NDUFB6(9p21.1 , 128aa) ; NDUFB7(19p13.12 , 137aa) ; NDUFB8(10q24.31 , 186aa) ; 
NDUFB9(8q24.13 , 179aa) ; NDUFB10(16p13.3 , 172aa) ; NDUFB11(Xp11.3 , 163aa) ; 
NDUFAB1(16p12.2 , 156aa) ; NDUFC1(4q31.1 , 76aa) ; NDUFC2(11q14.1 , 119aa) 
II SDHA(5p15.33 , 664aa) ;  SDHB(1p36.13 , 280aa) ; SDHC(1q23.3 , 169aa) ; SDHD(11q23.1 ,159aa) 
III 
UQCRB(8q22.1 , 111aa) ; UQCRH(1p33 , 91aa) ; UQCRQ(5q31.1 , 82aa) ; 
UQCRC1(3p21.31 , 480aa) ; UQCRC2(16p12.2 , 453aa) ; UQCR10(22q12.2 , 63aa); 
UQCR11(19p13.3 , 56aa) ; UQCRFS1(19q12 , 274aa) ; CYC1(8q24.3 , 325aa) ; 
CYCS(7p15.3 , 105aa) 
IV 
COX4-1(16q24.1 , 169aa) ; COX5a(15q24.2 , 150aa) ; COX5b(2q11.2 , 129aa) ; 
COX6a(12q24.31 , 109aa) ; COX6b(19q13.12 , 86aa) ; COX6c(8q22.2 , 75aa) ; 
COX7b(Xq21.1 , 80aa) ; COX7C(5q14.3 , 63aa) ;   COX8a(11q13.1 , 69aa) ; 
COX8c(14q32.12 , 72aa) 
V 
ATP5F1A) 18q21.1  , 553aa) ; ATP5F1B(12q13.3 , 529aa) ; ATP8A2(13q12.13 , 1188aa) ; 
ATP5F1D(19p13.3 , 168aa) ; ATP5F1E(20q13.32 , 51aa) ; ATP5PB(1p13.2 , 256aa) ; 
ATP5MC1(17q21.32 , 136aa) ; ATP5PD(17q25.1 , 161aa) ; ATP5ME(4p16.3 , 69aa) ; 
ATP5MF(7q22.1 , 94aa) ; ATP5MG(11q23.3 , 103aa) ; ATP5PF(21q21.3 , 108aa) ; 
ATP5IF1(1p35.3 , 106aa) ; ATP5PO(21q22.11 , 213aa) 
.
 
Complex Mitochondrial Genes  (location, Amino acid number) 
I 
ND1 ( 3307-4262 , 318aa ) ; ND2 ( 4470-5511 , 347aa ) ; ND3 ( 10059-10404 , 115aa ) ; 
ND4L ( 10470-10766 , 98aa) ; ND4 ( 10760-12137 , 459aa ) ; ND5 ( 12337-14148 , 603aa ) ; 
ND6 ( 14149-14673 , 174aa ) 
III cyt b ( 14747-15887 , 380aa) 
IV COXI ( 5904-7445 , 513aa ) ; COXII ( 7586-8269 , 227aa ) ; COXIII ( 9207-9990 , 261aa) 
V ATP6 ( 8527-9207 , 226aa ) ; ATP8 ( 8366-8572 , 68aa) 
Figure 1: The mtDNA genes related to OXPHOS complexes. Numbers represent the region in the mitochondrial 
genome where the gene begins. The D-loop region is located at 16024–16569 and 1–576. The below table indicates 
the size of the encoded proteins. 
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The occurrence of mtDNA replication is completely 
independent of the cell cycle and nuclear DNA 
replication.  DNA polymerase γ (POLG1 and 
POLG2) and mitochondrial transcription factor A 
(TFAM) are proteins that are encoded by nuclear 
genes and are required for mtDNA replication. 
Therefore, mutations in these genes can alter mtDNA 
content and ultimately disrupt their mitochondrial 
function (16, 17). However, mtDNA has a higher 
rate of mutation frequency due to the lack of repair 
system and/or histone proteins. The number and type 
of the mutations can influence various aspects of 
cellular bioenergetics (18).  
Less than 3% of the mtDNA is non-coding which 
mainly located in the displacement loop (D-loop) at 
16024–16569 and 1–576 (Figure 1). This area is 1.1 
kb in size and is associated with the replication and 
transcription of mtDNA which is regulated by 
transferred nuclear-encoded proteins (19). D-loop 
region is composed of two hyper-variable areas 
(HV1 and HV2) which are positioned at 16024-
16383 and 57-372, respectively (15, 20). Single 
nucleotide polymorphisms (SNPs) of the D-loop 
region including HV1 and HV2 were connected to 
the development of various cancers (20, 21). 
 
2. Variation aspects of mtDNA 
Polyplasmia is a fundamental characteristic of 
mtDNA which arises from its high CN compared to 
nDNA in the cell (10-10000 copies). Based on the 
distribution of normal or abnormal mtDNA between 
daughter cells, it results in homoplasmy (identical 
mtDNA variants) or heteroplasmy (different mtDNA 
variants) (18, 22). 
The ultimate dominant phenotype of the cell depends 
on both features of the mutation and the proportion 
of the heteroplasmy (23, 24). The heteroplasmy 
explains the diverse phenotypes between members of 
a family bearing an identical pathogenic mutation. 
Not only homoplasmic but also heteroplasmic 
mutations have been contributed to cancer cell 
progression (25, 26). Notably, pathogenic mtDNA 
mutations are mainly heteroplasmic, while benign 
polymorphisms usually represent homoplasmic 
status (27, 28). 
In addition to heteroplasmy, other essential 
variations are seen in mtDNA. Haplogroups are 
genetic groups with one or more specific mutations 
in mtDNA. They involve funder mutations inherited 
from a common ancestor (29). As it is presented in 
Figure 2, haplogroups M and N are derived from an 
African haplogroup called L3 and are known as the 
founders of all Eurasians. The most common 
haplogroups in modern African are L0-6, while HV 
and X are dominantly found in modern European. In 
the modern Asian populations, B, F, C, M, D and CZ 
haplogroups are mostly reported (30, 31). 
 
 
Figure 2: Human mtDNA haplogroups. Each 
haplogroup originates from a preceding haplogroup and 
remains part of it. Mitochondrial Eve is the matrilineal 
most recent common ancestor of all humans. 
 
3. mtDNA mutations and copy number variation 
in cancer 
Based on previous researches, mtDNA is ten times 
more susceptible to mutations than nDNA. Lack of 
the introns, histone proteins, and repair machinery in 
mtDNA could explain this finding. Both somatic and 
germline mtDNA substitutions are involved in a 
variety of cancers. Mutational mtDNA evaluation in 
1675 tumor samples revealed that C > T and A > G 
largely occur on the H-strand (3).  
The mtDNA mutations are either point mutations 
(deletions, insertions, substitutions) or mtDNA copy 
number variations (CNV) (32). The mutations that 
occur in the D-loop sequence cause changes in the 
CN of mtDNA. mtDNA CNV has been seen in many 
cancers, including breast cancer, colon cancer, 
hepatocellular carcinomas, and prostate cancer (33-
35). Factors that reduce mtDNA content include 
mutations in the D-loop region of the mtDNA and 
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mutations in the POLG which is encoded by the 
nuclear gene. These proteins are essential for the 
replication of the mitochondrial genome (36). Most 
cancers have some form of mtDNA-depleted or 
reduced status, although an increase in mtDNA CNV 
has also been reported (32). Environmental 
interfering factors can be the cause of this deviation. 
A recent study revealed that mtDNA CNV was 
significantly higher in HPV-positive cervical cancer 
patients than controls. HPV stimulates chronic ROS 
and mtDNA damage that implicate mitochondrial 
replication and CN in cervical cells (37). Using an 
array-based digital polymerase chain reaction (PCR) 
in ulcerative colitis-associated colorectal cancer 
(CRC), an increased mtDNA CNV was reported 
(38). 
The mtDNA variations have been studied from 
different aspects in tumorigenesis. A new study 
examined the response to chemotherapy medication 
in different mtDNA haplogroups by using 
transmitochondrial cybrids.  Transmitochondrial 
cybrids are cellular models to study the role of 
mitochondria in the same nuclear genome 
background with different mtDNA. They showed 
that following cisplatin treatment haplogroup J had 
lower levels of ROS than haplogroup H. In addition, 
haplogroup J was more sensitive to cisplatin, 
indicating that mtDNA is involved in the expression 
of genes influencing the resistance and side effects 
of cancer drugs (39). 
 
3.1. Breast cancer 
Breast cancer is one of the most prevalent cancers 
and the second factor of cancer mortality among 
women (40, 41). Estrogen receptor-negative (ER-) 
and progesterone receptor-negative (PR-) breast 
tumors exhibited more somatic mutations in the D-
loop region than estrogen receptor-positive (ER+) 
and progesterone-receptor positive (PR+) tumors 
(42). 
Earlier studies linked several large deletions of 
mtDNA including 4977bp and 4576bp deletions, to 
breast cancer pathogenesis (43). It has been shown 
that the majority of the mutations related to breast 
cancer are somatic mutations located in the D-loop 
region. The other reported mutations were in the 
ND1, ND4, ND5, and Cyt b genes (44). 
In 2011, a research study showed that two types of 
mtDNA mutations, the 12084C > T  in the ND4 and 
the 13966 A > G in the ND5 gene, reduce the activity 
of the complex І in the highly invasive MDA-MB-
231 cell line of breast cancer and ultimately impair 
mitochondrial function (9). 
Canter et al. reported that 10398A germline SNP 
located at ND3 gene along with other risk factors can 
be important in the case of breast cancer (45). Some 
additional studies confirmed 10398A > G SNP as a 
risk factor, while others have found no significant 
association between this SNP and breast cancer. A 
study by Darvishi et al. reported the mitochondrial 
allele 10398A as a risk factor for sporadic breast 
cancer as it elevates electron leakage rate and the 
overproduction of ROS (46). Czarnecka et al. found 
a higher frequency of the mitochondrial allele 
10398G in the Polish breast cancer patients than the 
control population and identified it as a risk factor 
(47). Contrary to these studies, Pezzotti et al. found 
no link between 10398A > G SNP and breast cancer 
susceptibility (48).  
Jiang et al. also reported no association between 
10398 A > G substitution and breast cancer. 
However, they observed decreased mtDNA content 
in premenopausal women with breast cancer (49). It 
had also been previously reported that a reduction in 
the mtDNA CN increased the production of ROS and 
mitochondrial impairment in breast tumors (42). 
Contrary to these results, in a prospective cohort with 
6-years separate blood sampling, higher mtDNA CN 
was associated with increased breast cancer risk (35). 
 
3.2. Gastric cancer 
Various genetic and epigenetic alterations such as 
microsatellite instability (MSI) are responsible for 
the development of gastric cancer which is the third 
cause of cancer mortality (50). It has been identified 
that the majority of mitochondrial somatic mutations 
were associated with increased MSI of the nDNA in 
gastric cancers (51). One of the earliest pieces of 
evidence indicating mtDNA involvement in gastric 
cancer was provided in 1995 by demonstrating a 
somatic 50-bp deletion in the D-loop region (52). 
Research study conducted by Wang et al. showed a 
significant association between gastric cancer and 
SNPs in D-loop including, 73G > A, 235A > G, 324C 
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> G, 16362T > C and 16519C > T (53). By analyzing 
peripheral blood leukocytes (PBL) Liao et al. 
observed no association between leukocyte mtDNA 
content and risk of gastric cancer. However, they 
identified that mtDNA CN can be important in the 
early stage of cancer progression (54).  
In late-stage tumors, increased mtDNA content 
showed a significant link to poor prognosis and 
worse survival of gastric cancer patients (55). These 
results were confirmed by the observation of the 
association between high mtDNA CN and increased 
gastric cancer risk in a Chinese population (56). 
In Gastroenteropancreatic Neuroendocrine 
Neoplasm (GEP-NEN), Er et al. identified survival 
SNPs including 16257C > A, and 150C > T located 
in the D-loop (57).  In a separate previous study by 
the same team, 73G, 150T, 151T, 492C, 16257A, 
16261T, and 16399G were recognized as the risk 
evaluation markers for GEP-NEN. They revealed the 
role of SNPs located in the D-loop region including 
7C > T in disease susceptibility (58). Moreover, an 
association between mitochondrial ND3 SNPs such 
as rs28358278 (10400C > T), rs2853826 (10398A > 
G), rs41467651 (10310G > A) and elevated risk of 
gastric cancer in Korean population has been shown 
(59). Interestingly, it has been identified that 
haplogroup N has a survival role in gastric cancer 
patients in comparison to haplogroup M (60). 
 
3.3. Prostate cancer 
Numerous studies have been performed to find 
diagnostic biomarkers in prostate cancer which is the 
second cause of cancer death in men, worldwide 
(61).  Earlier evidence showed that germline 
mutations of the COXI, the core catalytic subunit of 
cytochrome c oxidase (complex IV), were associated 
with the risk of prostate cancer. They reported COXI 
conserved amino acid mutations in 12% of prostate 
cancer samples. They also showed that 8993T > G 
mutation in ATP6 led to the accumulation of ROS 
and the progression of prostate cancer (62).  
mtDNA whole-genome sequencing (WGS) in 
prostate tumors revealed more than 40 somatic 
mutations in COXII, COXIII, ATP6, and ND6 
genes. The tRNAs gene alterations were linked to 
increased Prostate-specific antigen (PSA) (63).   
In 2013, Koochekpour and colleagues showed lower 
mtDNA in African American men compared to 
Caucasian American men, which could contribute to 
a higher risk and poor prognosis of prostate cancer 
(64). Further evidence confirmed that low mtDNA 
CN in PBL was involved in the invasive form of 
prostate cancer (65).  
The mtDNA WGS of 384 prostate cancer samples 
revealed at least one mitochondrial single nucleotide 
variant (mtSNV) for each patient, some of them 
related to the aggressive form of the tumor. This 
phenomenon was more detected in older patients. 
They also reported co-occurrence between mtDNA 
and nDNA profiles (66).  
In a paired benign/malignant prostate cancer survey, 
Schöpf et al. showed higher mtDNA mutations 
including complex I-encoding genes. Tumor 
transcriptome analysis revealed a significant link 
between mtDNA mutations and shorter patient 
survival (67). 
 
3.4 Colorectal cancer 
Another cancer associated with gene alterations in 
mtDNA is CRC which is the third most prevalent 
cancer in the world. One of the earliest proofs of 
mtDNA involvement in CRC was exhibited by an 
Iranian research study. They identified that 
individuals with a higher level of mtDNA variants 
are more susceptible to CRC (68).  In another article 
published by the same research group, 4216T > C in 
the ND1 gene has also been linked to CRC 
pathogenesis (69).  
In 2010, Theodoratou et al. reported that 752G > A, 
1440G > A variants located on the 12SrRNA gene 
and 4770G > A located on the ND2 gene were 
associated with the CRC prognosis and mortality 
(70).  
In a case-control study conducted on CRC, common 
SNPs of D-loop were investigated.  73G > A, 146T 
> C, 195T > C, 324C > G, 16261C > T, 16304T > C 
and 309C/C (insert) were showed significant 
correlation to the disease susceptibility (71).  
The mRNA expression levels of ND1, ND6, Cyt b, 
COXI, 12SrRNA, and ATP6 were tested by Reverse 
transcription (RT) PCR in CRC. The results indicate 
increased mRNA levels of all six genes with a more 
prominent elevation in COXI in late malignant 
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tissues (72). By sequencing the entire 1124 bp D-
loop region of CRC tumors, Govatati et al. found that 
most CRC-related SNPs are located in the HV1. 
They concluded that mutations in the D-loop region 
disrupt mitochondrial function and lead to increased 
production of ROS and oxidative stress (73). In 
2018, Thyogarajan et al. pointed out that SNPs 
including 16294C > T, 16296C > T, 16278C > T and 
16069C > T which are located in the HV1, were 
associated with the colorectal adenoma risk (74).  
In 2016, the mtDNA CNV association with the 
expression of P53 and TFAM were examined in 
CRC, precancerous tissues and 9 colorectal cancer 
cell lines. A significant correlation was observed 
between p53 and TFAM co-expression and 
clinicopathological characteristics of the patients. 
They also observed that p53 could increase TFAM 
expression by binding to the TFAM promoter, and 
their co-expression regulates the mtDNA CN (75). 
 
3.5 Renal cell carcinoma 
Research on Renal cell carcinoma (RCC) the most 
prevalent kidney cancer in adults identified the role 
of mtDNA mutations in cancer for the first time. 
Studies on Tumor samples of patients showed a 
heteroplasmic 294 bp deletion in the ND1 gene (76).  
In 2013, Xu et al. demonstrated that 16293A > G D-
loop variant linked to increased risk of early-onset 
RCC. The minor allele G was significantly correlated 
with the lower onset of the disease (77). Further 
investigation suggested some D-loop SNPs such as; 
16293A > G, 262A > G, 488T > C, 16298T > C and 
16319G > as the potential markers for RCC 
diagnosis and subgroups identification (78). The 
same research team further emphasized the role of 
262C > T SNP in the HV2 associated with poor RCC 
outcome (79). They also reported that mtMSI of the 
CCCCCTCTA at position 8272 was associated with 
the incidence of RCC (80).  
By a quantitative real-time PCR assay on PBL, 
Purdue et al. found a significant link between lower 
mtDNA CN and RCC susceptibility (81). They 
further conducted a nested case-control study and 
evaluated leukocyte mtDNA up to 13 years before 
diagnosis of CRC.  Interestingly, the results revealed 
high pre-diagnostic leukocyte mtDNA CN 
associated with an increased risk of the disease (82). 
3.6 Lung cancer 
Based on WHO report in 2020, lung cancer, with 
2.21 million cases, is the second most common, and 
with 1.80 million deaths is the most common cause 
of cancer mortality (https://www.who.int/news-
room/fact-sheets/detail/cancer).  
By analyzing the early-stage Non-Small Cell Lung 
Cancer (NSCLC), it has been shown that the 
haplogroup D/D4 were hotspots for somatic 
mutations linked to the disease survival (83). Ding et 
al. identified polymorphisms at 235A> G and 
324A/G correlated to increased risk of lung cancer 
and considered them as informant factors in a high-
risk population. They also reported 16298T> C 
located in the D-loop region is associated with small-
cell lung cancer (84). 
The Efficiency of plasma mtDNA copy number 
content as a biomarker for lung cancer was estimated 
in a recent study. The receiver operating 
characteristic (ROC) curve analysis revealed that 
plasma mtDNA content could detect lung cancer 
with a sensitivity and specificity of 71.1% and 
70.1%, respectively (85).  
By whole mitochondrial genome sequencing of 
NSCLC, Kazdal et al. found numerous non-
repetitive mtDNA somatic mutations. Largely 
variable mtDNA CN was also observed in different 
tumor segments with significantly lower load in solid 
predominant segments (86). This is while in a 
simultaneous study in NSCLC, increase and 
decreased total mtDNA CN was shown in the non-
tumor and tumor segments, respectively. They 
concluded that mtDNA plays a prominent role in the 
human NSCLC progression (87). 
Conclusion 
During the last decade, the contribution of mtDNA 
in cancer has been vastly investigated. Emerging 
evidence now supports the concept that mtDNA 
changes result in oxidative stress, free radical 
generation, and cancer progression. mtDNA 
mutations were considered the main cause of 
mitochondrial function abnormalities and inherited 
susceptibility to the diseases. Subsequent alterations 
in expressed proteins were noticed in the vast variety 
of solid tumors. Although cancer cells need 
mitochondria as the source of energy, the 
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mitochondrial dysfunction somehow acts in the 
direction of tumorigenesis. The accurate 
mechanisms of these manners are not clear yet; 
however, mtDNA molecular analysis may lead to 
discovering the driver mutations, functional 
perspectives and involved pathways. 
Future studies on mtDNA in the context of tumor 
development would be promising in cancer 
prevention and therapeutic approaches. 
Conflict of Interest 




This research received no external funding. 
Ethics 
Ethics code: IR.MODARES.REC.1399.131  
Authors Contributions 
Conceptualization, S.S., F.D., S.M. and L.G.; 
methodology, S.S., F.D., S.M. and L.G. and S.S., 
F.D., S.M. and L.G.; software, S.S., F.D., S.M. and 
L.G.; validation, S.S., F.D., S.M. and L.G.; 
investigation, S.S., F.D., S.M. and L.G. ; resources, 
S.S., F.D., S.M. and L.G.; data curation, S.S., F.D., 
S.M. and L.G.; writing—original draft preparation, 
S.S., F.D., S.M. and L.G.; writing—review and 
editing, S.S., F.D., S.M. and L.G. 
References 
1. Wallace DC. Mitochondrial DNA mutations 
in disease and aging. Environmental and Molecular 
Mutagenesis. 2010;51(5):440-50. 
2. Chandra D, Singh KK. Genetic insights into 
OXPHOS defect and its role in cancer. Biochimica et 
Biophysica Acta (BBA) - Bioenergetics. 
2011;1807(6):620-5. 
3. Ju YS, Alexandrov LB, Gerstung M, 
Martincorena I, Nik-Zainal S, Ramakrishna M, et al. 
Origins and functional consequences of somatic 
mitochondrial DNA mutations in human cancer. eLife. 
2014;3. 
4. Stewart JB, Alaei-Mahabadi B, Sabarinathan 
R, Samuelsson T, Gorodkin J, Gustafsson CM, et al. 
Simultaneous DNA and RNA Mapping of Somatic 
Mitochondrial Mutations across Diverse Human 
Cancers. PLoS genetics. 2015;11(6):e1005333. 
5. Kaipparettu BA, Ma Y, Park JH, Lee TL, 
Zhang Y, Yotnda P, et al. Crosstalk from non-
cancerous mitochondria can inhibit tumor properties of 
metastatic cells by suppressing oncogenic pathways. 
PloS one. 2013;8(5):e61747. 
6. Kühlbrandt W. Structure and function of 
mitochondrial membrane protein complexes. BMC 
Biology. 2015;13(1):89. 
7. Chiang SC, Meagher M, Kassouf N, 
Hafezparast M, McKinnon PJ, Haywood R, et al. 
Mitochondrial protein-linked DNA breaks perturb 
mitochondrial gene transcription and trigger free 
radical-induced DNA damage. Science advances. 
2017;3(4):e1602506. 
8. Schon EA, DiMauro S, Hirano M. Human 
mitochondrial DNA: roles of inherited and somatic 
mutations. Nature reviews Genetics. 2012;13(12):878-
90. 
9. Imanishi H, Hattori K, Wada R, Ishikawa K, 
Fukuda S, Takenaga K, et al. Mitochondrial DNA 
mutations regulate metastasis of human breast cancer 
cells. PloS one. 2011;6(8):e23401. 
10. Pfleger J, He M, Abdellatif M. Mitochondrial 
complex II is a source of the reserve respiratory 
capacity that is regulated by metabolic sensors and 
promotes cell survival. Cell Death & Disease. 
2015;6(7):e1835-e. 
11. Hartwell LH, Weinert TA. Checkpoints: 
controls that ensure the order of cell cycle events. 
Science (New York, NY). 1989;246(4930):629-34. 
12. Kalen AL, Ahmad IM, Abdalla MY, 
O’Malley YQ, Goswami PC, Sarsour EH. MnSOD and 
Cyclin B1 Coordinate a Mito-Checkpoint during Cell 
Cycle Response to Oxidative Stress. Antioxidants. 
2017;6(4):92. 
13. Kulawiec M, Ayyasamy V, Singh KK. p53 
regulates mtDNA copy number and mitocheckpoint 
pathway. Journal of carcinogenesis. 2009;8:8. 
14. Nagano H, Hashimoto N, Nakayama A, 
Suzuki S, Miyabayashi Y, Yamato A, et al. p53-
inducible DPYSL4 associates with mitochondrial 
supercomplexes and regulates energy metabolism in 
adipocytes and cancer cells. Proceedings of the 
National Academy of Sciences. 2018;115(33):8370-5. 
15. Anderson S, Bankier AT, Barrell BG, de 
Bruijn MH, Coulson AR, Drouin J, et al. Sequence and 
organization of the human mitochondrial genome. 
Nature. 1981;290(5806):457-65. 
A Review on the Role of Mitochondrial DNA Mutations in Cancer                                                             Dahi F, et al. 
Archives of Medical Laboratory Sciences; Volume 7, 2021 (Continuous Volume)  9 
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License 
16. Kang I, Chu CT, Kaufman BA. The 
mitochondrial transcription factor TFAM in 
neurodegeneration: emerging evidence and 
mechanisms. FEBS letters. 2018;592(5):793-811. 
17. Kunkel GH, Chaturvedi P, Tyagi SC. 
Mitochondrial pathways to cardiac recovery: TFAM. 
Heart failure reviews. 2016;21(5):499-517. 
18. D'Souza AR, Minczuk M. Mitochondrial 
transcription and translation: overview. Essays in 
biochemistry. 2018;62(3):309-20. 
19. Jemt E, Persson Ö, Shi Y, Mehmedovic M, 
Uhler JP, Dávila López M, et al. Regulation of DNA 
replication at the end of the mitochondrial D-loop 
involves the helicase TWINKLE and a conserved 
sequence element. Nucleic Acids Research. 
2015;43(19):9262-75. 
20. Mercer TR, Neph S, Dinger ME, Crawford J, 
Smith MA, Shearwood AM, et al. The human 
mitochondrial transcriptome. Cell. 2011;146(4):645-
58. 
21. Williams SB, Ye Y, Huang M, Chang DW, 
Kamat AM, Pu X, et al. Mitochondrial DNA Content as 
Risk Factor for Bladder Cancer and Its Association with 
Mitochondrial DNA Polymorphisms. Cancer 
prevention research (Philadelphia, Pa). 2015;8(7):607-
13. 
22. Lightowlers RN, Chinnery PF, Turnbull DM, 
Howell N. Mammalian mitochondrial genetics: 
heredity, heteroplasmy and disease. Trends in genetics 
: TIG. 1997;13(11):450-5. 
23. Stewart JB, Chinnery PF. The dynamics of 
mitochondrial DNA heteroplasmy: implications for 
human health and disease. Nature Reviews Genetics. 
2015;16(9):530-42. 
24. Floros VI, Pyle A, Dietmann S, Wei W, Tang 
WCW, Irie N, et al. Segregation of mitochondrial DNA 
heteroplasmy through a developmental genetic 
bottleneck in human embryos. Nature Cell Biology. 
2018;20(2):144-51. 
25. Beadnell TC, Scheid AD, Vivian CJ, Welch 
DR. Roles of the mitochondrial genetics in cancer 
metastasis: not to be ignored any longer. Cancer 
metastasis reviews. 2018;37(4):615-32. 
26. Chatterjee A, Mambo E, Sidransky D. 
Mitochondrial DNA mutations in human cancer. 
Oncogene. 2006;25(34):4663-74. 
27. Yuan Y, Ju YS, Kim Y, Li J, Wang Y, Yoon 
CJ, et al. Comprehensive molecular characterization of 
mitochondrial genomes in human cancers. Nature 
Genetics. 2020;52(3):342-52. 
28. Tan DJ, Bai RK, Wong LJ. Comprehensive 
scanning of somatic mitochondrial DNA mutations in 
breast cancer. Cancer research. 2002;62(4):972-6. 
29. Weissensteiner H, Pacher D, Kloss-
Brandstätter A, Forer L, Specht G, Bandelt HJ, et al. 
HaploGrep 2: mitochondrial haplogroup classification 
in the era of high-throughput sequencing. Nucleic 
Acids Res. 2016;44(W1):W58-63. 
30. Quintana-Murci L, Semino O, Bandelt H-J, 
Passarino G, McElreavey K, Santachiara-Benerecetti 
AS. Genetic evidence of an early exit of Homo sapiens 
sapiens from Africa through eastern Africa. Nature 
Genetics. 1999;23(4):437-41. 
31. Loogväli EL, Roostalu U, Malyarchuk BA, 
Derenko MV, Kivisild T, Metspalu E, et al. Disuniting 
uniformity: a pied cladistic canvas of mtDNA 
haplogroup H in Eurasia. Molecular biology and 
evolution. 2004;21(11):2012-21. 
32. Reznik E, Miller ML, Şenbabaoğlu Y, Riaz N, 
Sarungbam J, Tickoo SK, et al. Mitochondrial DNA 
copy number variation across human cancers. eLife. 
2016;5. 
33. Hu L, Yao X, Shen Y. Altered mitochondrial 
DNA copy number contributes to human cancer risk: 
evidence from an updated meta-analysis. Scientific 
Reports. 2016;6(1):35859. 
34. Kalsbeek AMF, Chan EKF, Corcoran NM, 
Hovens CM, Hayes VM. Mitochondrial genome 
variation and prostate cancer: a review of the 
mutational landscape and application to clinical 
management. Oncotarget. 2017;8(41):71342-57. 
35. Lemnrau A, Brook MN, Fletcher O, Coulson 
P, Tomczyk K, Jones M, et al. Mitochondrial DNA 
Copy Number in Peripheral Blood Cells and Risk of 
Developing Breast Cancer. Cancer research. 
2015;75(14):2844-50. 
36. Achanta G, Sasaki R, Feng L, Carew JS, Lu 
W, Pelicano H, et al. Novel role of p53 in maintaining 
mitochondrial genetic stability through interaction with 
DNA Pol gamma. The EMBO journal. 
2005;24(19):3482-92. 
37. Sun W, Qin X, Zhou J, Xu M, Lyu Z, Li X, et 
al. Mitochondrial DNA copy number in cervical 
exfoliated cells and risk of cervical cancer among HPV-
positive women. BMC Women's Health. 
2020;20(1):139. 
38. Tanaka T, Kobunai T, Yamamoto Y, Murono 
K, Otani K, Yasuda K, et al. Increased Copy Number 
Variation of mtDNA in an Array-based Digital PCR 
Assay Predicts Ulcerative Colitis-associated Colorectal 
Cancer. In vivo (Athens, Greece). 2017;31(4):713-8. 
A Review on the Role of Mitochondrial DNA Mutations in Cancer                                                             Dahi F, et al. 
Archives of Medical Laboratory Sciences; Volume 7, 2021 (Continuous Volume)  10 
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License 
39. Patel TH, Norman L, Chang S, Abedi S, Liu 
C, Chwa M, et al. European mtDNA Variants Are 
Associated With Differential Responses to Cisplatin, an 
Anticancer Drug: Implications for Drug Resistance and 
Side Effects. Frontiers in oncology. 2019;9:640. 
40. Shahbazi S, Alavi S, Majidzadeh AK, 
Ghaffarpour M, Soleimani A, Mahdian R. BsmI but not 
FokI polymorphism of VDR gene is contributed in 
breast cancer. Medical oncology (Northwood, London, 
England). 2013;30(1):393. 
41. Mohamadalizadeh-Hanjani Z, Shahbazi S, 
Geranpayeh L. Investigation of the SPAG5 gene 
expression and amplification related to the NuMA 
mRNA levels in breast ductal carcinoma. World 
Journal of Surgical Oncology. 2020;18(1):225. 
42. Tseng LM, Yin PH, Chi CW, Hsu CY, Wu 
CW, Lee LM, et al. Mitochondrial DNA mutations and 
mitochondrial DNA depletion in breast cancer. Genes, 
chromosomes & cancer. 2006;45(7):629-38. 
43. Zhu W, Qin W, Sauter ER. Large-scale 
mitochondrial DNA deletion mutations and nuclear 
genome instability in human breast cancer. Cancer 
Detect Prev. 2004;28(2):119-26. 
44. Parrella P, Xiao Y, Fliss M, Sanchez-
Cespedes M, Mazzarelli P, Rinaldi M, et al. Detection 
of mitochondrial DNA mutations in primary breast 
cancer and fine-needle aspirates. Cancer research. 
2001;61(20):7623-6. 
45. Canter JA, Kallianpur AR, Parl FF, Millikan 
RC. Mitochondrial DNA G10398A polymorphism and 
invasive breast cancer in African-American women. 
Cancer research. 2005;65(17):8028-33. 
46. Darvishi K, Sharma S, Bhat AK, Rai E, 
Bamezai RN. Mitochondrial DNA G10398A 
polymorphism imparts maternal Haplogroup N a risk 
for breast and esophageal cancer. Cancer letters. 
2007;249(2):249-55. 
47. Grzybowska-Szatkowska L, Slaska B. 
Mitochondrial NADH dehydrogenase polymorphisms 
are associated with breast cancer in Poland. Journal of 
applied genetics. 2014;55(2):173-81. 
48. Pezzotti A, Kraft P, Hankinson SE, Hunter DJ, 
Buring J, Cox DG. The mitochondrial A10398G 
polymorphism, interaction with alcohol consumption, 
and breast cancer risk. PloS one. 2009;4(4):e5356. 
49. Jiang H, Zhao H, Xu H, Hu L, Wang W, Wei 
Y, et al. Peripheral blood mitochondrial DNA content, 
A10398G polymorphism, and risk of breast cancer in a 
Han Chinese population. Cancer science. 
2014;105(6):639-45. 
50. Behroozi J, Shahbazi S, Bakhtiarizadeh MR, 
Mahmoodzadeh H. ADAR expression and copy 
number variation in patients with advanced gastric 
cancer. BMC gastroenterology. 2020;20(1):152. 
51. Hiyama T, Tanaka S, Shima H, Kose K, 
Tuncel H, Ito M, et al. Somatic mutation in 
mitochondrial DNA and nuclear microsatellite 
instability in gastric cancer. Oncology reports. 
2003;10(6):1837-41. 
52. Burgart LJ, Zheng J, Shu Q, Strickler JG, 
Shibata D. Somatic mitochondrial mutation in gastric 
cancer. The American journal of pathology. 
1995;147(4):1105-11. 
53. Wang H, Wang Y, Zhao Q, Guo Z, Zhang F, 
Zhao Y, et al. Identification of sequence 
polymorphisms in the D-Loop region of mitochondrial 
DNA as a risk factor for gastric cancer. Mitochondrial 
DNA Part A, DNA mapping, sequencing, and analysis. 
2016;27(2):1045-7. 
54. Liao LM, Baccarelli A, Shu XO, Gao YT, Ji 
BT, Yang G, et al. Mitochondrial DNA copy number 
and risk of gastric cancer: a report from the Shanghai 
Women's Health Study. Cancer epidemiology, 
biomarkers & prevention : a publication of the 
American Association for Cancer Research, 
cosponsored by the American Society of Preventive 
Oncology. 2011;20(9):1944-9. 
55. Zhang G, Qu Y, Dang S, Yang Q, Shi B, Hou 
P. Variable copy number of mitochondrial DNA 
(mtDNA) predicts worse prognosis in advanced gastric 
cancer patients. Diagnostic pathology. 2013;8:173. 
56. Zhu X, Mao Y, Huang T, Yan C, Yu F, Du J, 
et al. High mitochondrial DNA copy number was 
associated with an increased gastric cancer risk in a 
Chinese population. Molecular carcinogenesis. 
2017;56(12):2593-600. 
57. Er LM, Li Y, Er L, Wu M, Zheng XL, Guo ZJ, 
et al. Associations between Single Nucleotide 
Polymorphisms in the Mitochondrial DNA D-Loop 
Region and Outcome of Gastroenteropancreatic 
Neuroendocrine Neoplasm. Annals of clinical and 
laboratory science. 2018;48(3):333-7. 
58. Er LM, Wu ML, Gao Y, Wang SJ, Li Y. 
Identification of sequence polymorphisms in the 
displacement loop region of mitochondrial DNA as a 
risk factor for gastroenteropancreatic neuroendocrine 
neoplasm. Journal of clinical laboratory analysis. 
2017;31(5). 
59. Jin EH, Sung JK, Lee SI, Hong JH. 
Mitochondrial NADH Dehydrogenase Subunit 3 
(MTND3) Polymorphisms are Associated with Gastric 
Cancer Susceptibility. International journal of medical 
sciences. 2018;15(12):1329-33. 
60. Wang C, Wang Y, Wang H, Zhang R, Guo Z. 
Mitochondrial DNA haplogroup N is associated good 
A Review on the Role of Mitochondrial DNA Mutations in Cancer                                                             Dahi F, et al. 
Archives of Medical Laboratory Sciences; Volume 7, 2021 (Continuous Volume)  11 
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License 
outcome of gastric cancer. Tumour biology : the journal 
of the International Society for Oncodevelopmental 
Biology and Medicine. 2014;35(12):12555-9. 
61. Shahbazi S, Khorasani M, Mahdian R. Gene 
expression profile of FVII and AR in primary prostate 
cancer. Cancer biomarkers : section A of Disease 
markers. 2016;17(3):353-8. 
62. Petros JA, Baumann AK, Ruiz-Pesini E, Amin 
MB, Sun CQ, Hall J, et al. mtDNA mutations increase 
tumorigenicity in prostate cancer. Proceedings of the 
National Academy of Sciences of the United States of 
America. 2005;102(3):719-24. 
63. Kloss-Brandstätter A, Schäfer G, Erhart G, 
Hüttenhofer A, Coassin S, Seifarth C, et al. Somatic 
mutations throughout the entire mitochondrial genome 
are associated with elevated PSA levels in prostate 
cancer patients. American journal of human genetics. 
2010;87(6):802-12. 
64. Koochekpour S, Marlowe T, Singh KK, 
Attwood K, Chandra D. Reduced mitochondrial DNA 
content associates with poor prognosis of prostate 
cancer in African American men. PloS one. 
2013;8(9):e74688. 
65. Tu H, Gu J, Meng QH, Kim J, Davis JW, He 
Y, et al. Mitochondrial DNA copy number in peripheral 
blood leukocytes and the aggressiveness of localized 
prostate cancer. Oncotarget. 2015;6(39):41988-96. 
66. Hopkins JF, Sabelnykova VY, Weischenfeldt 
J, Simon R, Aguiar JA, Alkallas R, et al. Mitochondrial 
mutations drive prostate cancer aggression. Nature 
Communications. 2017;8(1):656. 
67. Schöpf B, Weissensteiner H, Schäfer G, 
Fazzini F, Charoentong P, Naschberger A, et al. 
OXPHOS remodeling in high-grade prostate cancer 
involves mtDNA mutations and increased succinate 
oxidation. Nature Communications. 2020;11(1):1487. 
68. Akouchekian M, Houshmand M, Hemati S, 
Ansaripour M, Shafa M. High rate of mutation in 
mitochondrial DNA displacement loop region in human 
colorectal cancer. Diseases of the colon and rectum. 
2009;52(3):526-30. 
69. Akouchekian M, Houshmand M, Akbari MH, 
Kamalidehghan B, Dehghan M. Analysis of 
mitochondrial ND1 gene in human colorectal cancer. 
Journal of research in medical sciences : the official 
journal of Isfahan University of Medical Sciences. 
2011;16(1):50-5. 
70. Theodoratou E, Din FV, Farrington SM, 
Cetnarskyj R, Barnetson RA, Porteous ME, et al. 
Association between common mtDNA variants and all-
cause or colorectal cancer mortality. Carcinogenesis. 
2010;31(2):296-301. 
71. Guo Z, Zhao S, Fan H, Du Y, Zhao Y, Wang 
G. Identification of sequence polymorphisms in the D-
Loop region of mitochondrial DNA as a risk factor for 
colon cancer. Mitochondrial DNA Part A, DNA 
mapping, sequencing, and analysis. 2016;27(6):4244-5. 
72. Wallace L, Mehrabi S, Bacanamwo M, Yao X, 
Aikhionbare FO. Expression of mitochondrial genes 
MT-ND1, MT-ND6, MT-CYB, MT-COI, MT-ATP6, 
and 12S/MT-RNR1 in colorectal adenopolyps. Tumour 
biology : the journal of the International Society for 
Oncodevelopmental Biology and Medicine. 
2016;37(9):12465-75. 
73. Govatati S, Saradamma B, Malempati S, Dasi 
D, Thupurani MK, Nagesh N, et al. Association of 
mitochondrial displacement loop polymorphisms with 
risk of colorectal cancer in south Indian population. 
Mitochondrial DNA Part A, DNA mapping, 
sequencing, and analysis. 2017;28(5):632-7. 
74. Thyagarajan B, Guan W, Fedirko V, Barcelo 
H, Ramasubramaian R, Gross M, et al. Associations of 
mitochondrial polymorphisms with sporadic colorectal 
adenoma. Molecular carcinogenesis. 2018;57(5):598-
605. 
75. Wen S, Gao J, Zhang L, Zhou H, Fang D, Feng 
S. p53 increase mitochondrial copy number via up-
regulation of mitochondrial transcription factor A in 
colorectal cancer. Oncotarget. 2016;7(46). 
76. Horton TM, Petros JA, Heddi A, Shoffner J, 
Kaufman AE, Graham SD, Jr., et al. Novel 
mitochondrial DNA deletion found in a renal cell 
carcinoma. Genes, chromosomes & cancer. 
1996;15(2):95-101. 
77. Xu J, Guo Z, Zhang J, Cui L, Zhang S, Bai Y. 
Single nucleotide polymorphisms in the mitochondrial 
displacement loop and age-at-onset of renal cell 
carcinoma. Sci Rep. 2013;3:2408. 
78. Zhang J, Guo Z, Bai Y, Cui L, Zhang S, Xu J. 
Identification of sequence polymorphisms in the 
displacement loop region of mitochondrial DNA as a 
risk factor for renal cell carcinoma. Biomedical reports. 
2013;1(4):563-6. 
79. Bai Y, Guo Z, Xu J, Liu S, Zhang J, Cui L, et 
al. Single nucleotide polymorphisms in the D-loop 
region of mitochondrial DNA is associated with renal 
cell carcinoma outcome. Mitochondrial DNA. 
2015;26(2):224-6. 
80. Bai Y, Guo Z, Xu J, Zhang J, Cui L, Zhang H, 
et al. The 9-bp deletion at position 8272 in region V of 
mitochondrial DNA is associated with renal cell 
carcinoma outcome. Mitochondrial DNA Part A, DNA 
mapping, sequencing, and analysis. 2016;27(3):1973-5. 
81. Purdue MP, Hofmann JN, Colt JS, Hoxha M, 
Ruterbusch JJ, Davis FG, et al. A case-control study of 
A Review on the Role of Mitochondrial DNA Mutations in Cancer                                                             Dahi F, et al. 
Archives of Medical Laboratory Sciences; Volume 7, 2021 (Continuous Volume)  12 
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License 
peripheral blood mitochondrial DNA copy number and 
risk of renal cell carcinoma. PloS one. 
2012;7(8):e43149. 
82. Hofmann JN, Hosgood HD, 3rd, Liu CS, 
Chow WH, Shuch B, Cheng WL, et al. A nested case-
control study of leukocyte mitochondrial DNA copy 
number and renal cell carcinoma in the Prostate, Lung, 
Colorectal and Ovarian Cancer Screening Trial. 
Carcinogenesis. 2014;35(5):1028-31. 
83. Wang Z, Choi S, Lee J, Huang YT, Chen F, 
Zhao Y, et al. Mitochondrial Variations in Non-Small 
Cell Lung Cancer (NSCLC) Survival. Cancer 
informatics. 2015;14(Suppl 1):1-9. 
84. Ding C, Li R, Wang P, Jin P, Li S, Guo Z. 
Identification of sequence polymorphisms in the D-
loop region of mitochondrial DNA as a risk factor for 
lung cancer. Mitochondrial DNA. 2012;23(4):251-4. 
85. Chen J, Zhang L, Yu X, Zhou H, Luo Y, Wang 
W, et al. Clinical application of plasma mitochondrial 
DNA content in patients with lung cancer. Oncology 
letters. 2018;16(6):7074-81. 
86. Kazdal D, Harms A, Endris V, Penzel R, 
Kriegsmann M, Eichhorn F, et al. Prevalence of 
somatic mitochondrial mutations and spatial 
distribution of mitochondria in non-small cell lung 
cancer. British Journal of Cancer. 2017;117(2):220-6. 
87. Lin CS, Lee MC, Hsu JC, Pan SC, Wei YH. 
AB001. Low mitochondrial DNA copy number is 
associated with low mitochondrial DNA integrity and 
advanced T-status in non-small cell lung cancer. 
Journal of Thoracic Disease. 2017;9(Suppl 14). 
 
 
